MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4
MiMedx Group, Inc. (Nasdaq: MDXG) will announce its first-quarter financial results on May 3, 2022, after market close. Senior management will review these results in a conference call on May 4, 2022, at 8:30 a.m. Eastern Time. MiMedx specializes in placental tissue allografts for treating chronic wounds and musculoskeletal conditions, employing proprietary methods like the PURION® process. Since inception, over two million allografts have been distributed.
- Significant experience with over two million allografts distributed, indicating established operational capabilities.
- Focus on innovative placental tissue engineering positions the company for growth in healthcare sectors.
- None.
MARIETTA, Ga., April 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 3, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, May 4, 2022, beginning at 8:30 a.m. Eastern Time.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13728444
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com
Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com
FAQ
When will MDXG report its first-quarter earnings for 2022?
What time will the MDXG conference call take place?
How can I access the MDXG earnings call?
What is the focus of MiMedx Group, Inc.?
